TTS Pharma

About TTS Pharma

TTS Pharma is a UK-based company, established in 2012, that operates as a vertically integrated supply chain manager in the cannabinoid sector. The company specializes in the cultivation, manufacturing, and development of legal and regulated cannabis-derived active agents for the wellness, nutraceutical, and pharmaceutical industries. Its business model focuses on providing a transparent 'crop to shop' supply chain, ensuring the production of high-quality, fully compliant cannabinoid products, including bulk active pharmaceutical ingredients (APIs) and finished goods. TTS Pharma serves the food, cosmetics, and nutraceutical markets by supplying purified cannabinoid components.

The company was incorporated to acquire and develop drug delivery and diagnostic technologies, and it has since validated processes for extracting, separating, and tracing the active ingredients from industrial hemp. In May 2019, TTS Pharma announced it had closed a £10.3 million Series B funding round to expand its supply chain, develop facilities, and strengthen partnerships. The company's management team includes Executive Chairman Paul Atherton, who joined in 2019 and has a background in corporate finance and the international natural resource sectors, and CEO Mark Tucker. Another key figure is Robin Emerson, Director of Business Development, whose advocacy for medicinal cannabis is inspired by his daughter's successful treatment with it.

TTS Pharma's product offerings include high-purity CBD isolate, CBD distillate, and custom-formulated CBD oils and blends for sublingual use, food supplements, and cosmetics. The company was the first in the UK to produce commercial cannabidiol free of illegal THC and CBN. A significant milestone was forming the first Primary Authority (PA) partnership in the UK for CBD products with Hertfordshire County Council Trading Standards in February 2020, which provides 'Assured Advice' for its product lines. TTS Pharma is headquartered in Liverpool, UK.